Opaleye Management as of Sept. 30, 2015
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the September 2015 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Chimerix (CMRX) | 5.8 | $12M | 310k | 38.20 | |
Ultragenyx Pharmaceutical (RARE) | 5.2 | $11M | 110k | 96.31 | |
Cempra | 4.9 | $10M | 360k | 27.84 | |
Axogen (AXGN) | 4.3 | $8.7M | 2.1M | 4.12 | |
Medgenics | 4.1 | $8.3M | 1.1M | 7.82 | |
AMAG Pharmaceuticals | 3.9 | $7.9M | 200k | 39.73 | |
Imprimis Pharmaceuticals | 3.8 | $7.7M | 1.2M | 6.42 | |
Ariad Pharmaceuticals | 3.8 | $7.7M | 1.3M | 5.84 | |
Retrophin | 3.7 | $7.5M | 370k | 20.26 | |
Fibrogen (FGEN) | 3.5 | $7.1M | 325k | 21.92 | |
Supernus Pharmaceuticals (SUPN) | 3.2 | $6.5M | 460k | 14.03 | |
Zs Pharma | 3.1 | $6.2M | 95k | 65.66 | |
Inotek Pharmaceuticals Corp conv | 3.0 | $6.0M | 643k | 9.40 | |
Cara Therapeutics (CARA) | 2.9 | $5.9M | 415k | 14.29 | |
Codexis (CDXS) | 2.7 | $5.5M | 1.6M | 3.39 | |
Eagle Pharmaceuticals (EGRX) | 2.7 | $5.4M | 73k | 74.03 | |
Flamel Technologies | 2.5 | $5.1M | 310k | 16.31 | |
Geron Corporation (GERN) | 2.5 | $5.0M | 1.8M | 2.76 | |
Neurocrine Biosciences (NBIX) | 2.5 | $5.0M | 125k | 39.78 | |
Protalix Biotherapeutics Inc note 4.500% 9/1 | 2.1 | $4.3M | 3.6M | 1.18 | |
Ophthotech | 2.1 | $4.3M | 105k | 40.52 | |
Affimed Therapeutics B V | 1.8 | $3.6M | 590k | 6.17 | |
Cytrx | 1.8 | $3.6M | 1.5M | 2.37 | |
Intec Pharma | 1.7 | $3.5M | 630k | 5.60 | |
Amarin Corporation (AMRN) | 1.7 | $3.4M | 1.8M | 1.93 | |
Zogenix | 1.7 | $3.4M | 250k | 13.50 | |
Trillium Therapeutics, Inc. Cmn | 1.6 | $3.2M | 245k | 13.03 | |
Tonix Pharmaceuticls | 1.5 | $3.0M | 570k | 5.29 | |
Blueprint Medicines (BPMC) | 1.4 | $2.8M | 130k | 21.34 | |
Adamas Pharmaceuticals | 1.4 | $2.8M | 166k | 16.74 | |
Momenta Pharmaceuticals | 1.3 | $2.6M | 160k | 16.41 | |
Tg Therapeutics (TGTX) | 1.3 | $2.6M | 260k | 10.08 | |
Agile Therapeutics | 1.3 | $2.6M | 385k | 6.74 | |
Avinger | 1.3 | $2.6M | 175k | 14.71 | |
Nivalis Therapeutics | 1.1 | $2.3M | 175k | 12.97 | |
XOMA CORP Common equity shares | 1.1 | $2.2M | 3.0M | 0.75 | |
Foamix Pharmaceuticals | 1.0 | $2.1M | 285k | 7.33 | |
Tenax Therapeutics | 0.9 | $1.9M | 635k | 3.00 | |
Accelr8 Technology | 0.8 | $1.5M | 95k | 16.18 | |
Auris Med Hldg | 0.6 | $1.3M | 355k | 3.56 | |
Xenon Pharmaceuticals (XENE) | 0.6 | $1.2M | 151k | 8.26 | |
Sage Therapeutics (SAGE) | 0.4 | $846k | 20k | 42.30 | |
Evoke Pharma | 0.4 | $757k | 260k | 2.91 | |
Innocoll | 0.3 | $695k | 56k | 12.51 | |
Celgene Corp right 12/31/2011 | 0.3 | $547k | 340k | 1.61 | |
Alder Biopharmaceuticals | 0.3 | $527k | 16k | 32.73 | |
Cynapsus Therapeutics | 0.2 | $469k | 29k | 16.17 | |
Biolinerx Ltd-spons | 0.2 | $383k | 250k | 1.53 | |
Tracon Pharmaceuticals | 0.1 | $119k | 12k | 9.78 |